The Bcl-2 (B-Cell Lymphoma 2) Inhibitors Market is being driven by Rising geriatric population globally
The Bcl-2 (B-Cell Lymphoma 2) Inhibitors Market is expected to grow at a CAGR of 15.2% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 2288.9 million. VENCLEXTA, a leading drug in the BCL-2 inhibitors category, is transforming the treatment landscape for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Acute Myeloid Leukemia (AML) patients. However, the substantial cost of this therapy poses a significant challenge for both patients and the healthcare system. In response, various organizations, including governments and non-profits, as well as pharmaceutical companies, are implementing initiatives to offer financial and clinical support for CLL/SLL and AML treatment. Genentech, for instance, introduced the BioOncology Co-pay program, which extends financial assistance to patients with specified disease states. The annual cost of VENCLEXTA treatment for CLL/SLL and AML ranges from USD20,000 to USD25,000.
Get more information on Bcl-2 (B-Cell Lymphoma 2) Inhibitors Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
175 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 15.2% |
|
Market growth 2024-2028 |
USD 2288.9 million |
|
Market structure |
fragmentation |
|
YoY growth 2023-2024(%) |
12.86 |
|
Key countries |
US, Canada, Germany, UK, and France |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
The Bcl-2 (B-Cell Lymphoma 2) inhibitors market is witnessing significant growth due to the commercialization of novel drugs for the treatment of various types of cancer. These agents, which target the Bcl-2 protein, are becoming essential components of cancer therapeutics, particularly in the treatment of B-cell lymphomas such as Positive Lymphoma and Follicular Lymphoma. Novel drugs like Venetoclax are gaining popularity due to their effectiveness in monotherapy and in combination therapy with chemotherapeutic drugs and immunotherapy drugs. However, the use of these drugs comes with side effects such as diarrhea and nausea. Pharmerging markets are expected to play a key role in the growth of the Bcl-2 inhibitors market, as the incidence of cancer is on the rise in these regions. The World Health Organisation estimates that over 1.8 million new cases of lymphoma were diagnosed worldwide in 2020. The development of personalized medicine and the identification of BCL-2 mutations are also expected to drive the growth of the market. Other cancer types such as Cutaneous T-cell lymphoma are also being explored as potential indications for Bcl-2 inhibitors. Despite the potential benefits, the use of Bcl-2 inhibitors comes with toxic substances that can harm patients. Therefore, it is crucial for pharmaceutical companies to adopt effective commercialization strategies to ensure the safe and effective use of these drugs in cancer treatment.
In the expansive global biotechnology industry, Bcl-2 (B-Cell Lymphoma 2) Inhibitors represent a significant segment. This market falls under the larger umbrella of the parent biotechnology market, which encompasses entities involved in the research and development (R&D) or production of various biotech offerings, including biologics, biosimilars, bio-betters, and biotech reagents. According to Technavio's market analysis, the global healthcare sector's size is determined by the consolidated revenue generated by manufacturers and providers of healthcare equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. The healthcare market's growth is propelled by several key factors, among which is the increasing global population aging. By 2050, approximately one-quarter of the US population and by 2030 in Europe are projected to be over 60 years old. This demographic shift will create substantial demand for healthcare solutions, including Bcl-2 Inhibitors, to address the unique health needs of the aging population.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
